Meetings - The ASCO Post

Two Studies Highlight Benefits in Quality of Life and Symptom Management With Novel Treatments of Advanced Breast Cancer

Recent improvements in overall and progression-free survival for patients with HER2-positive and estrogen receptor–positive breast cancers have not come at the expense of quality of life or symptom ma...

Breast Cancer

By Chase Doyle / June 10, 2023 / ESMO Breast Cancer Annual Congress 2023

Two Studies of Atezolizumab-Based Regimens in Early-Stage, Triple-Negative and HER2-Positive Breast Cancers

Immunotherapy regimens involving the PD-L1 monoclonal antibody atezolizumab have demonstrated promising results in patients with early-stage, triple-negative breast cancer and HER2-positive breast can...

Breast Cancer

By Chase Doyle / June 10, 2023 / ESMO Breast Cancer Annual Congress 2023

HER3-Targeting Antibody-Drug Conjugates Show Encouraging Results in Breast Cancer Subtypes

Early-phase data from the SOLTI TOT-HER3 and ICARUS-BREAST01 trials suggest that the novel HER3-directed antibody-drug conjugate patritumab deruxtecan may have beneficial activity in patients with hor...

ESMO Breast Cancer Annual Congress 2023

Two Studies Highlight Benefits in Quality of Life and Symptom Management With Novel Treatments of Advanced Breast Cancer

Two Studies of Atezolizumab-Based Regimens in Early-Stage, Triple-Negative and HER2-Positive Breast Cancers

HER3-Targeting Antibody-Drug Conjugates Show Encouraging Results in Breast Cancer Subtypes

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma

Neuro-Oncology Guidelines Reveal How AI Could Improve Brain Cancer Diagnosis Monitoring and Treatment

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer